Allot to Release First Quarter 2025 Results and Host Conference Call on May 12, 2025
By GlobeNewswire Published on April 28, 2025, 14:05 IST
Hod Hasharon, Israel, April 28, 2025 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative security-as-a-service (SECaaS) and network intelligence solutions for communication service providers (CSPs) and enterprises, announced today that it will host a conference call to discuss its first quarter 2025 results on Monday, May 12, 2025 at 9:00AM ET (2:00PM UK, 4:00PM Israel).
The unaudited financial results of the quarter will be published prior to the commencement of the conference call.
To access the conference call, please dial one of the following numbers:
US: 1-888-642-5032, UK: 0-800-917-5108, Israel: +972-3-918-0644
A live webcast of the conference call can be accessed on the Allot website at http://investors.allot.com/. The webcast will also be archived on the website following the conference call.
About Allot
Allot Ltd. (NASDAQ: ALLT, TASE: ALLT) is a provider of leading innovative converged cybersecurity solutions and network intelligence for service providers and enterprises worldwide, enhancing value to their customers. Our solutions are deployed globally for network and application analytics, traffic control and shaping, network-based security services, and more. Allot's multi-service platforms are deployed by over 500 mobile, fixed and cloud service providers and over 1000 enterprises. Our industry-leading network-based security as a service solution is already used by many millions of subscribers globally.
Allot. See. Control. Secure.
For more information, visit www.allot.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from the 180mg cohort of the Company's SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with CIndU at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. Briquilimab (subcutaneous) administration resulted in deep disease control at 180mg, with 12 of 12 participants (100%) enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants (66%) achieving clinical response by week 2, and 7 of 12 participants (58%) maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported in the 180mg cohort. 'We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'In addition to the responses observed, we are pleased that briquilimab continued to be well tolerated in the study. Taken together with the results observed thus far in the BEACON study in CSU, these data demonstrate the ability of briquilimab to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms, along with a potentially differentiated safety profile. On behalf of the entire Jasper team, I'd like to thank both the investigators and the patients who participated in SPOTLIGHT, along with their families and caregivers.' SPOTLIGHT Study Design and Data Summary: The SPOTLIGHT study is a Phase 1b/2a open label clinical trial evaluating a single dose of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD), the two most prevalent sub types of CIndU, who are refractory to antihistamines. The study enrolled 27 participants across three dose cohorts, 40mg (n=3), 120mg (n=12), and 180mg (n=12). The primary endpoints are safety and tolerability of briquilimab and secondary endpoints are focused on clinical activity and PK/PD, including measurement of serum tryptase. Among the 12 participants enrolled in the 180mg cohort, 3 were diagnosed with ColdU (25%) and 9 with SD (75%). Participants had high disease burden as assessed by provocation threshold testing. In the 180mg cohort, mean baseline TempTest® threshold was 18.7°C (range: 10-26°C) for ColdU participants, and mean baseline FricTest® threshold was 3.7 of 4 (range: 3-4) for SD participants. 12 of 12 participants (100%) enrolled in the 180mg dose cohort achieved a clinical response to provocation testing within the 8-week preliminary analysis period following treatment. 11 of 12 participants (92%) treated in the cohort achieved a complete response (CR) with either their critical temperature threshold improving to at least 4°C for ColdU participants or their FricTest® score improving to 0 for SD participants, and 1 of 12 participants achieved a partial response (PR) as their best response. Complete responses in TempTest® or FricTest® were observed as early as 1 week following dosing in the 180mg cohort, with 8 of 12 participants (66%) achieving CR or PR by week 2. Overall, 22 of 27 participants (81%) enrolled in the study achieved a CR and 26 of 27 participants (96%) achieved a CR or PR. Briquilimab40mg(n=3) Briquilimab120mg(n=12) Briquilimab180mg(n=12) BriquilimabAll doses (n=27) Complete Response, n (%) 1 (33.3%) 10 (83.3%) 11 (91.6%) 22 (81.5%) ColdU, n 0 3 3 6 Symptomatic Dermographism, n 1 7 8 16 Partial Response, n (%) 2 (66.7%) 1 (8.3%) 1 (8.4%) 4 (14.8%) ColdU, n 1 0 0 1 Symptomatic Dermographism, n 1 1 1 3 Complete or Partial Response at any time, n (%) 3 (100%) 11 (91.6%) 12 (100%) 26 (96.3%) At the 8-week timepoint following treatment, 7 of 12 (58%) participants in the 180mg cohort maintained an ongoing clinical response, with 5 participants achieving CR and 2 participants achieving PR. Mean baseline serum tryptase for participants in the 180mg cohort was 5.1 ng/ml (standard deviation: 2.29 ng/ml). Significant reductions in tryptase were observed as early as the week 1 assessment and were correlated with the onset of clinical responses. Tryptase measurements below the lower limit of quantification were observed in 10 of 12 participants (83%) in the 180mg cohort. Briquilimab was well tolerated in the study. No SAEs or AEs ≥ grade 3 were reported in the 180mg cohort. Furthermore, there were no reported AEs related to hair or skin color changes. 2 of 12 participants (17%) enrolled in the 180mg cohort experienced taste change/hypogeusia. Mild, transient drops in neutrophil counts were observed, with 6 of 12 participants (50%) experiencing grade 1 or grade 2 neutrophil count decreases which resolved in a median of 16 days. 5 of the 6 participants who experienced neutrophil count decreases were diagnosed with concurrent viral infections that may have contributed to observed decreases. 'It is exciting to see additional clinical data showing that treatment with briquilimab can lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population,' said Martin Metz, M.D., Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin. 'Notably, the safety and tolerability results observed in both the SPOTLIGHT and BEACON studies thus far show that the adverse events possibly caused by briquilimab are mostly low frequency, low grade, and resolve quickly. Patients with CIndU currently have very few treatment options, and I look forward to continuing to support the development of novel therapeutics to treat this debilitating disease.' Conference Call / Webinar Jasper will host a conference call and webinar on Monday, June 16, 2025, at 8:00 a.m. EDT. A live question and answer session with management will follow the formal presentations. A link to the webinar, including presentation slides, can be found here. To access the live conference call via phone, dial 1-844-826-3033 from the US or 1-412-317-5185 from outside the US, or click here. The conference ID is 10200147, and the conference call passcode is 6392607. The presentation slides and a link to the live and archived webinar will also be available on the Events & News – Events page of Jasper's Investor Relations website. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; briquilimab's ability to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms along with a potentially differentiated safety profile; and the potential for treatment with briquilimab to lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@ Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@ Lauren Walker (media) Real Chemistry 646-564-2156 lbarbiero@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Refrigeration Oil Market to Reach USD 2.01 billion by 2032
Rising eco-friendly refrigerant adoption, stringent emission norms propel Refrigeration Oil demand; digitization in cold-chain bolsters market growth. Austin, June 14, 2025 (GLOBE NEWSWIRE) -- The Refrigeration Oil Market Size was valued at USD 1.38 billion in 2024 and is expected to reach USD 2.01 billion by 2032, growing at a CAGR of 4.86% over the forecast period of 2025-2032. Global Shift Toward Eco-Friendly Cooling Fuels Refrigeration Oil Demand Across Residential, Commercial, and Industrial Applications Increasing use of sophisticated cooling systems and rising environmental regulations are the factors driving the Refrigeration Oil Market. Demand for high-efficiency synthetic options is being driven by the U.S. EPA 2023 requirement to phase down high-GWP oils. A growing industrial sector in Asia Pacific and a 15% increase in synthetic oil production in China in 2023 are driving growth. Yet domestic consumption in the U.S. DOE report showed a 12% overall increase in oil used for HVAC, and Carrier's 2024 forecast projects increased shipments of biodegradable PDF Sample of Refrigeration Oil Market @ The U.S. Refrigeration Oil Market had the highest CAGR of 6.25% in the forecast period of 2025-2032, with a market size of USD 244 million. In the U.S., rising energy-efficient HVAC retrofits supported by the Department of Energy's (DoE) 2023 Green Building Initiative is driving the use of Refrigeration Oil. In late 2023, major carriers such as Honeywell and Emerson introduced low-GWP synthetic oils to meet the increasingly stringent EPA regulations and growing healthcare sector refrigeration demand. Key Players: Shell plc ExxonMobil Corporation Phillips 66 Company Chevron Phillips Chemical Company LLC Rompetrol Rafinare S.A. Sumitomo Chemical Co., Ltd. Honeywell International Inc. Junyuan Petroleum Group Merck KGaA Indian Oil Corporation Limited. Refrigeration Oil Market Report Scope: Report Attributes Details Market Size in 2024 USD 1.38 Billion Market Size by 2032 USD 2.01 Billion CAGR CAGR of 4.86% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Drivers • Growth In Cold Chain Logistics and Food Storage Drives the Market Growth. If You Need Any Customization on Refrigeration Oil Market Report, Inquire Now @ By Type, Synthetic Type Refrigeration Oil Dominated the Refrigeration Oil Market in 2024 with a 48% Market Share. The dominance is owing to their thermal stability, environmental compatibility and EPA conformability. Chevron Phillips Chemical developed enhanced PAO blends that increased compressor efficiency and decreased loss. The U.S. Energy Information Administration found a 22% increase in the use of synthetic oil in hospitals and data centers, pointing to increasing demand for precise cooling. Mineral oils are being gradually replaced by biodegradable synthetic oils, due to the R&D dedicated to low-GWP refrigerant compatibility and long-term performance. By Application, the Refrigerators dominated the Refrigeration Oil Market in 2024 with a 32% Market Share. The dominance is attributed to the market is determined by the adoption of energy efficient models in North America and Asia Pacific. U.S. sales of refrigerators increased by 8%, and makers of brands like Whirlpool and LG began to install inverter compressors, which need high-performance lubricants. With consumers looking to conserve energy, reduce cost, and extend the life of their appliances, there is a heightened demand for specifically formulated refrigeration oils that combat wear and sludge throughout the category. Asia Pacific dominated the Refrigeration Oil Market in 2024, Holding a 39% Market Share. The dominance of the region is on account of fast industrialization and growing cold-chain industry in China and India. China turned out 18 percent more synthetic oil and India exported 12% more to Southeast Asia. Government incentives also contributed, including tax breaks in Thailand for energy-efficient storage that helped generate investments in chillers. Regional OEM activity also increased with Daikin opening the first dedicated synthetic oil plant in Malaysia in 2024, continuing the dominance of the region in refrigeration oil demand and production. North America is the fastest-growing region in the Refrigeration Oil Market in 2024, holding the Highest CAGR. Growth is the result of EPA regulations requiring the reduced use of high-GWP oils and a retro fit wave in commercial refrigeration. Emerson introduced chlorine-free PAOs in response, as U.S. commercial HVAC oil use rose 18% compared to last year. Consumption of synthetic oil in the data center market in Canada also increased by 10%, indicating a broader regional trend towards more sustainable, higher performing refrigeration oil solutions across critical infrastructure Full Research Report @ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
KOORUI Launches 34-Inch Curved Monitor 34E6UC Globally, Empowering Hybrid Work and Immersive Entertainment
NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) — Monitor brand KOORUI proudly presents the 34E6UC, a 34-inch ultra-wide curved display designed to elevate both productivity and entertainment. A 34-inch ultra-wide WQHD curved monitor designed to meet the growing demand for hybrid work tools and immersive digital experiences. *KOORUI 34E6UC Launches 34″ 180Hz Curved Display to Power Hybrid Work and Home Entertainment As remote work and home entertainment become popular trends, consumers are seeking display solutions that support seamless multitasking, vivid visuals, and ergonomic comfort. According to IDC, demand for ultra-wide monitors has grown over 15% year-over-year, driven by professionals, gamers, and digital creators. KOORUI 34E6UC meets the rising demand for immersive, high-performance displays with a 3440×1440 WQHD resolution that delivers razor-sharp detail and enhanced workspace. Its 1000R curved screen wraps around the viewer's field of vision, creating a deeply immersive experience—perfect for cinematic entertainment and focused multitasking. The 180Hz refresh rate ensures ultra-smooth visuals, especially in fast-paced games where every frame counts, while the 1ms MPRT minimizes motion blur for sharp, responsive action. HDR400 certification further enhances image quality with richer contrast, deeper blacks, and more vibrant colors—ideal for both content creation and media consumption. Designed with versatility in mind, the monitor covers 90% of the DCI-P3 and 125% of the sRGB color gamuts, offering professional-grade color accuracy for designers, video editors, and digital artists. Its ergonomic stand supports height, tilt, and swivel adjustments, allowing users to maintain optimal posture and comfort during long hours of work or play. '34E6UC was built to bridge productivity and entertainment in one expansive screen,' said by KOORUI Brand Manager Mr. Hunter. 'It's designed to support everything from professional workflows to immersive gameplay.' The 34E6UC is now available on Amazon US, and is featured as a key pick for Prime Day 2025, offering consumers access to premium specs at highly competitive value. About KOORUI Powered by HKC's semiconductor display expertise, KOORUI blends innovative panel manufacturing with human-centered product design. Its monitor lineup empowers creators, gamers, and professionals around the globe with reliable, high-performance visual solutions. Press Contact: [email protected] A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
